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Surveillance for infection by endoscopy for variant CJD and other
human prion diseases
T
he agents responsible for transmissi-
ble spongiform encephalopathies or
prion diseases target the central
nervous system, but their unique nature
and pathophysiology has meant that
prion diseases have made an impact in
disciplines as diverse as dentistry and
transfusion medicine, in large measure
because of their resistance to decontami-
nation by conventional means.1
In 1996, a new variant form of
Creutzfeldt–Jakob disease (CJD) was
described in the UK that preferentially
affects young adults, resulting in a
disease that often presents with psychia-
tric symptoms progressing to ataxia,
dementia and terminating in akinetic
mutism.2 The cause of this disease was
proposed to be oral exposure to the
bovine encephalopathy (BSE) agent, and
subsequent studies have only served to
strengthen this link, with no credible
alternative explanation having been pro-
posed.3–6 All human prion diseases are
progressive and uniformly fatal neurode-
generative conditions, and, in the case of
the acquired forms (iatrogenic CJD and
kuru), associated with potentially very
long incubation periods.7 Host genetics
substantially influence these diseases:
familial prion diseases are closely asso-
ciated with mutations in the prion protein
gene (PRNP), and the methionine /valine
polymorphism at PRNP codon 129
appears to influence susceptibility, incu-
bation period and in some respects dis-
ease phenotype.7
Our understanding of the pathogenesis
of prion diseases has been greatly aided
by the development of methods to detect
and localise abnormal forms of the prion
protein (PrPSc), which is the major, if not
the sole, component of the infectious
agent.7 Variations of standard immuno-
histochemical methods and Western blot-
ting that use protease digestion and other
discriminant steps to distinguish between
the ubiquitous normal form of the prion
protein (PrPC) and PrPSc have been used.
With such tools, the distribution of this
protease-resistant PrP (PrPres) in vCJD
has been found to be much broader than
in other forms of CJD, involving the
lymphoreticular system including the
tonsil, appendix, lymph nodes, compo-
nents of the peripheral nervous system
and all the gut-associated lymphoid
tissue (fig 1).8 9 Animal models of prion
diseases suggest that lymphoreticular
tissues are involved early in the incuba-
tion period when the infection is asymp-
tomatic, and examination of archival
appendicectomy tissues from patients
who went on to develop variant CJD
showed that lymphoreticular involvement
can predate clinical symptoms by years.10
KNOWN UNKNOWNS
A number of uncertainties rapidly became
associated with variant CJD: What pro-
portion of the UK population had been
exposed to BSE? Would all exposures
result in neurological disease, and if so
what would the incubation period be?
Were those infected with BSE a risk to
others via iatrogenic transmission, and if
so by which routes and how might one
assess the risk? What measures might
reasonably be put in place to counteract
these risks?
The numbers of cases of variant CJD
have not reached the heights predicted by
some, and new cases have been in decline
since a peak in 1999 (www.cjd.ed.ac.uk/
figures.htm), but there have been unwel-
come developments regarding the poten-
tial for secondary infection. A
retrospective analysis of tonsil and appen-
dix tissue from the general population
suggests that a prevalence infection is
higher than would be predicted from the
disease incidence data alone.11 On the
basis of such studies of peripheral invol-
vement, infection is now considered not
to be limited to those of the MM PRNP
codon 129 genetic subgroup of the popu-
lation.12 13 Moreover, it now seems likely
that blood transfusion from donors in the
preclinical phase of variant CJD is infec-
tious.12 14 Taken together, these data
suggest a worrying scenario in which a
considerable number of people in the
normal UK population may be infected
with BSE and unknowingly pose a risk to
others through blood transfusion, organ
donation, surgery or even dentistry. Given
the likely incubation periods involved,
even significant numbers of such cases
might not be seen for many years to
come.
One of the difficulties associated with
formulating proportionate risk reduction
measures involves the translation of
experimental data, such as that presented
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Figure 1 Widespread distribution of abnormal prion protein in lymphoid follicles throughout the
digestive tract (A), tonsil (B), ileum (C), appendix (D) and large intestine. All stained with the anti-prion
protein antibody 12F10 (positive labelling is brown).
COMMENTARIES 9
www.gutjnl.com
by Wadsworth et al,15 (see page 90) to the
clinical situation involving the relation-
ship between markers such as PrPres and
the actual parameter of interest, in this
case human infectivity. These can become
compounded by other differences
between the situation facing patients
and clinicians and those from which the
data have been derived. Wadsworth et al
should be congratulated for tackling this
problem head on, in the context of
possible infectivity in the rectum of
patients with variant CJD.15 The authors
have taken autopsy specimens of brain
and rectum from a patient with variant
CJD, measured the PrPres load by Western
blotting and attempted transmission via
the intracerebral route to two lines of
transgenic mice carrying the human prion
protein gene. Although these mice lack a
species barrier with respect to the prion
protein sequence and overexpress the
gene product, when challenged with
variant CJD brain they do not develop a
clinical spongiform encephalopathy.
Instead, they seem to propagate detect-
able levels of PrPres in the absence of
frank disease (a so-called subclinical
infection). Owing to this, an end-point
titration of infectivity is not possible.
What the data do however show is that
PrPres is detectable in the brains of
recipient animals that were challenged
with a variant CJD rectal inoculum that
contains 1024.7 of the amount of PrPres
found in the corresponding brain.
Admittedly, to detect this low level, a
PrPres concentration step was required.
The article shows that this specimen of
variant CJD rectum has sufficient infec-
tivity to precipitate molecular pathologi-
cal changes in over half of the recipient
animals, assuming that the authors have
not simply recovered their initial inocu-
lum. In this respect, the specimens, both
brain and rectum, have been shown to be
infectious, but to show a quantitative
linear relationship between PrPres and
infectivity more than two data points will
be required and a model susceptible to
disease would be desirable. It will be
interesting to see whether tissue speci-
mens with PrPres loads intermediate
between brain and rectum, such as tonsil,
spleen and lymph node, do indeed indi-
cate a quantitative relationship between
PrPres load and infectivity, but substantial
additional work will be required to justify
this claim.
How concerned should we be by these
findings? The link between PrPres accu-
mulation and secondary lymphoid folli-
cles has been known for some time,
including those in gut-associated lym-
phoid tissues.8–10 16–18 The finding of very
low levels of PrPres in rectal specimens,
where lymphoid tissue is relatively sparse
compared with the distal ileum, might
therefore be predicted.8 18 That PrPres
found in variant CJD lymphoid tissues
(including tonsil and spleen) can trans-
mit disease to wild-type mice is also well
recognised.19 What the article by
Wadsworth et al tells us is that the risk
of iatrogenic transmission from rectal
tissue is more than theoretical.
However, the conditions under which
the experiments were performed and
those which pertain in clinical practice
differ. The experimental challenge was
intracerebral, which is impossible to
conceive of in terms of exposure resulting
from reuse of a contaminated endoscope
in humans. The experimental conditions
used (including overexpression of the
PRNP) favoured successful transmission.
Although there is a body of work on oral
exposure to the scrapie and BSE agents,
the point of entry through the gut wall is
as yet ill defined, although it is a topic of
considerable recent investigation.20 21
UNKNOWN UNKNOWNS?
The foregoing investigation notwithstand-
ing, it is worth pointing out that the study
of prion diseases has confounded expecta-
tion on previous occasions. For some, BSE
posed little or no threat to the human
population. Similarly, thorough and
repeated evaluations of the risk posed by
blood transfusion concluded that the risk of
transmission by this route was negligible.22
This last example is perhaps instructive and
involved a threefold response to what was
considered at the time a hypothetical risk:
firstly, the introduction of precautionary
measures to reduce the risk23 24; Secondly,
the funding of extensive and long-term
animal studies to assess the likelihood of
transmission by this route25–27; and lastly,
an active national surveillance system
working in concert with the blood transfu-
sion service to trace and link any potentially
affected blood donors and recipients
(www.cjd.ed.ac.uk/TMER).
THE PRESENT
How should these findings influence
current measures to reduce the risk of
variant CJD transmission by gastrointest-
inal endoscopy in UK, both from sympto-
matic patients and from those identified
as ‘‘at increased risk’’ of variant CJD? The
numbers in the latter category vastly
outnumber the former, and include sev-
eral thousands of people who may have
been exposed to variant CJD infectivity by
contaminated instruments, blood compo-
nents and plasma products. The risk of
transmission is not confined to the use of
the endoscope itself, as accessories such
as biopsy forceps may come into close
contact with lymphoid follicles in the
gut submucosa that may harbour prion
infectivity. Guidance on the measures to
reduce the risks of prion transmission via
endoscopes was revised in 2005 and is
available on the Department of Health
website at: www.advisorybodies.doh.gov.
uk/acdp/tseguidance/Index.htm (Annex
F). Since this guidance assumed that
gastrointestinal lymphoid tissues were of
‘‘medium risk’’ in terms of prion infectiv-
ity (the brain is ‘‘high risk’’), the results
from the article by Wadsworth et al do not
justify any additional precautions.15
As endoscopes cannot be autoclaved for
reuse, procedures that are deemed likely
to be invasive and potentially contami-
nate endoscopes with prion infectivity
(thus requiring quarantine of the endo-
scope) include endoscopy and biopsy, or
endoscopy with any use of diathermy or
argon plasma coagulation. Procedures
deemed non-invasive (thus not requiring
quarantine of the endoscope) include
endoscopy without biopsy, or with brush
cytology, or endoscopy with injection of
varices (without diathermy), or with
mucosal clipping or banding of varices.
In general, these steps should not com-
promise patient care; dedicated endo-
scopes are available from the National
CJD Surveillance Unit for use on patients
with vCJD who require insertion of a
polyethylene glycol feeding tube.
THE FUTURE
Although prion agents are notoriously
difficult to inactivate by conventional
methods that are effective for bacteria
and viruses, recent research has identified
several novel approaches to removing
proteins and prions from the surfaces of
metal instruments that might be applic-
able to endoscopes. These include inno-
vative processes such as the use of gas
plasmas and various combinations of
detergents and enzymes,28–30 These seem
particularly interesting, as reductions in
prion infectivity on metal surfaces have
been measured after their use. However,
it remains to be shown whether any of
these techniques are readily applicable to
endoscopes and whether the promising
results in experimental laboratories can
be maintained on use in a clinical setting.
Further studies on the safety, toxicity and
long-term effects of these methods will
also be required before any of them can
reach general clinical use. However, the
prospects of developing an ‘‘anti-prion’’
process applicable to endoscopes seem
much more promising now than even a
few years ago.
Although no evidence of transmission
of variant CJD infectivity by endoscopy
(or any other medical or surgical device)
has yet been identified, continuing
surveillance is required for variant CJD
and other human prion diseases in the
10 COMMENTARIES
www.gutjnl.com
UK, particularly in view of the lengthy
incubation periods that can be associated
with transmission of these diseases.7
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